lexprikson.com → mean get → symptoms signs some → what are the symptoms of medullary thyroid cancer
Posted on by Brendan Ortega

What Are the Symptoms of Medullary Thyroid Cancer

Close-up of a medical ultrasound showing a thyroid nodule with irregular borders

Medullary thyroid cancer (MTC) is a rare form of thyroid cancer that arises from the parafollicular C cells, which produce calcitonin. Symptoms often develop slowly and may mimic benign conditions, making early detection challenging. The disease can present with a palpable neck mass, persistent hoarseness, or gastrointestinal issues such as diarrhea. Elevated calcitonin levels are a key diagnostic marker.

MTC accounts for about 3-4% of all thyroid cancers. Unlike papillary or follicular thyroid cancers, MTC does not take up iodine, so radioactive iodine scans are ineffective for imaging or treatment. This distinction affects both diagnosis and management strategies.

Because MTC originates in C cells, it frequently causes hormonal imbalances. Patients may experience episodes of flushing, diarrhea, or abdominal pain due to excess hormone secretion. These symptoms are often misattributed to irritable bowel syndrome or anxiety, delaying proper evaluation.

How Medullary Thyroid Cancer Presents

The most common initial sign is a painless lump or swelling in the neck, typically detected during a routine physical exam or self-examination. The mass may grow slowly over months and is often firm to touch. In some cases, it's discovered incidentally during imaging for unrelated reasons, such as a CT scan for chest pain.

Hoarseness lasting more than two weeks is another red flag. It results from tumor invasion of the recurrent laryngeal nerve, which controls vocal cord movement. Persistent voice changes should prompt referral to an ENT specialist, especially if accompanied by a neck mass.

Diarrhea occurs in approximately 20-30% of patients with MTC. It is often watery, frequent, and not related to food intake. This symptom stems from excessive calcitonin and other peptides like chromogranin A, which affect gut motility. Diarrhea may precede the discovery of a neck mass by several months.

Key Biomarkers and Diagnostic Clues

Calcitonin is the primary tumor marker for MTC. Normal fasting calcitonin levels are below 10 pg/mL. Levels above 100 pg/mL strongly suggest MTC, while values between 10-100 pg/mL require further investigation. A stimulated calcitonin test-where calcitonin is measured after pentagastrin or calcium infusion-can improve sensitivity in borderline cases.

Chromogranin A is another useful marker. It's elevated in about 80% of MTC cases and correlates with tumor burden. However, it's not specific to MTC and can rise in renal failure, chronic stress, or other neuroendocrine tumors.

A 2021 study published in *The Journal of Clinical Endocrinology & Metabolism* found that 45% of MTC patients had normal calcitonin levels at diagnosis, underscoring the need for clinical correlation and imaging when symptoms persist.

Types and Patterns of Presentation

MTC occurs in two forms: sporadic and hereditary. Sporadic MTC accounts for 75-80% of cases and typically presents in individuals aged 40-60. Hereditary MTC is linked to RET proto-oncogene mutations and is part of multiple endocrine neoplasia syndromes (MEN2A and MEN2B).

Hereditary MTC often appears earlier-sometimes in childhood-and is associated with additional features:

Patients with MEN2B may present with a prominent tongue, thickened lips, and a high-arched palate. These physical traits are distinct from sporadic MTC and should trigger genetic testing.

Common Misdiagnoses and Red Flags

Due to overlapping symptoms, MTC is frequently misdiagnosed. Chronic diarrhea is often treated as irritable bowel syndrome or lactose intolerance. Hoarseness may be attributed to acid reflux or vocal strain. Neck masses are sometimes dismissed as cysts or lymphadenopathy.

A 2019 case series from the Mayo Clinic reported that 38% of MTC patients received at least one incorrect diagnosis before the correct one. The average delay was 14 months. Early recognition reduces the risk of metastasis to lymph nodes, lungs, or liver.

Red flags include:

If any of these exist, calcitonin testing should be performed. A level above 10 pg/mL warrants a fine-needle aspiration biopsy of the thyroid nodule.

Real-World Example: A Delayed Diagnosis

In 2017, a 44-year-old woman presented with intermittent diarrhea and a 3-month history of hoarseness. She had been treated for GERD and prescribed proton-pump inhibitors. A CT scan revealed a 2.5 cm mass in the left lobe of the thyroid. Calcitonin was 180 pg/mL. Biopsy confirmed MTC with cervical lymph node involvement.

She underwent total thyroidectomy and central neck dissection. Post-op calcitonin dropped to undetectable levels. Follow-up imaging showed no evidence of residual disease. Her case highlights how non-specific symptoms can mask a serious condition.

When I reviewed her chart, I noted that she had no family history of endocrine tumors. This is typical-most MTC cases are sporadic. But the persistence of symptoms despite standard treatment should have triggered a workup earlier.

When to Seek Evaluation

Any persistent neck mass, especially if growing or hard, requires prompt assessment. Hoarseness lasting longer than three weeks demands otolaryngologic evaluation. Unexplained diarrhea, particularly if associated with weight loss or fatigue, should prompt blood tests for calcitonin and chromogranin A.

Genetic counseling and RET testing are recommended for patients with a family history of MTC or MEN2 syndromes. Early identification allows prophylactic thyroidectomy in children at risk, preventing cancer development.

Recognizing the symptoms of medullary thyroid cancer early improves outcomes. A neck lump, persistent hoarseness, or unexplained diarrhea should not be ignored. With timely intervention, survival rates exceed 90% at 10 years when disease is localized.


Related Posts